SECURITIESFORM AND EXCHANGE COMMISSION8-K

Item 2.02 Results of Operations and Financial Condition.

IfItem an9.01 emergingFinancial growthStatements company,and indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange ActExhibits. ☐

UNITED ~~STATES~~STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549

~~WASHINGTON,~~CURRENT ~~D.C. 20549~~REPORT

~~FORM~~Pursuant ~~8-K~~to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~CURRENT~~Date ~~REPORT~~of Report (Date of earliest event reported): November 06, 2025

~~Pursuant~~Climb toBio, ~~Section 13 or 15(d)~~Inc.

(Exact name of ~~the~~Registrant ~~Securities~~as ~~Exchange~~Specified ~~Act~~in ofIts ~~1934~~Charter)

Date of Report (Date of earliest event reported): October 17, 2025


Delaware	001-40708	83-2273741
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

20 William Street Suite 145
Wellesley Hills, Massachusetts		02481
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s ~~CLIMB~~Telephone ~~BIO~~Number, ~~INC.~~Including Area Code: (866) 857-2596

~~(Exact~~Not ~~Name of Registrant as Specified in its Charter)~~Applicable

Delaware		001-40708		83-2273741
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

(Former Name or Former Address, if Changed Since Last Report)

20 William Street, Suite 145 Wellesley Hills, Massachusetts		02481
(Address of Principal Executive Offices)		(Zip Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

~~Registrant’s~~☐Written ~~Telephone~~communications ~~Number,~~pursuant ~~Including~~to ~~Area~~Rule ~~Code:~~425 under the Securities Act (~~866)~~17 ~~857-2596~~CFR 230.425)

~~Not~~☐Soliciting ~~Applicable~~material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

~~(Former~~☐Pre-commencement ~~Name~~communications orpursuant ~~Former~~to ~~Address,~~Rule if14d-2(b) ~~Changed~~under ~~Since~~the ~~Last~~Exchange ~~Report~~Act (17 CFR 240.14d-2(b))

~~Check the appropriate box below if the Form 8~~☐Pre-Kcommencement ~~filing~~communications ispursuant ~~intended~~ to ~~simultaneously~~Rule ~~satisfy~~13e-4(c) ~~the~~under ~~filing obligation of~~ the ~~registrant~~Exchange ~~under~~Act ~~any~~(17 ofCFR ~~the following provisions:~~240.13e-4(c))

☐Securities ~~Written~~registered ~~communications~~ pursuant to ~~Rule~~Section ~~425~~12(b) ~~under~~of the ~~Securities~~ Act ~~(17 CFR 230.425)~~:

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	CLYM	The Nasdaq Stock Market LLC

☐Indicate ~~Pre-commencement~~by ~~communications~~check ~~pursuant~~mark towhether the registrant is an emerging growth company as defined in Rule ~~14d-2~~405 of the Securities Act of 1933 (b§ 230.405 of this chapter) ~~under~~or Rule 12b-2 of the Securities Exchange Act ~~(17~~of ~~CFR~~1934 (§ 240.~~14d~~12b-2(b of this chapter)).

☐Emerging ~~Pre-commencement~~growth ~~communications~~company ~~pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))~~☒

~~Securities~~If ~~registered~~an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 12 13(ba) of the Exchange Act:. ☐

Title of each class		TradingSymbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		CLYM		The Nasdaq Stock Market LLC (The Nasdaq Global Market)

~~Indicate~~On byNovember ~~check~~6, ~~mark~~2025, ~~whether~~Climb ~~the~~Bio, ~~registrant~~Inc. is(the an“Company”) ~~emerging~~issued ~~growth~~a ~~company~~press asrelease ~~defined~~announcing inits ~~Rule~~financial ~~405~~results offor the ~~Securities~~quarter ~~Act~~ended ofSeptember ~~1933~~30, ~~(§ 230~~2025.~~405~~ ofA ~~this~~copy ~~chapter) or Rule 12b-2~~ of the ~~Securities~~press ~~Exchange~~release ~~Act~~is ofattached ~~1934~~hereto (§as ~~240~~Exhibit 99.~~12b-2~~1 ofand ~~this~~incorporated ~~chapter)~~by reference herein.

~~Emerging~~The ~~growth~~information ~~company ☒~~in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether filed before or after the date hereof and regardless of any general incorporation language in such filing.

Climb Bio, Inc.

Date: October 17, 2025

/s/ Aoife Brennan

Aoife Brennan, M.B., Ch.B.

President and Chief Executive Officer

~~Item~~(d) 8Exhibits.01 ~~Other Events.~~

On October 17, 2025, Climb Bio, Inc. (the “Company”) issued a press release announcing the publication of an abstract providing new long-term follow-up clinical data for budoprutug, a novel anti-CD19 monoclonal antibody in development for B-cell mediated diseases. The follow-up clinical data from the previously conducted Phase 1b clinical trial (NCT04652570) of budoprutug in primary membranous nephropathy demonstrated long-term control of proteinuria for up to three years after initial dosing in four patients who received up to four doses of budoprutug. Additionally, in three of the patients, no further immunosuppressive treatment was required. In the trial, no treatment-related adverse events grade 3 or higher were observed.


Exhibit Number		Description
99.1		Press release of Climb Bio, Inc., dated November 6, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

~~Forward-Looking Statements~~ SIGNATURES

~~This~~Pursuant ~~Current~~to ~~Report on Form 8-K contains “forward-looking statements” within~~ the ~~meaning~~requirements of the ~~Private~~ Securities ~~Litigation~~Exchange ~~Reform~~ Act of ~~1995~~1934, ~~including without limitation statements regarding: future expectations, plans and prospects for~~ the ~~Company;~~registrant ~~expectations~~has ~~regarding~~duly ~~the~~caused ~~therapeutic~~this ~~benefits,~~report clinical potential and clinical development of budoprutug and CLYM116; and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” “will,” “working” and similar expressions. Forward-looking statements are based on management’s current expectations of future events and are subject to abe ~~number~~signed of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, important risks and uncertainties associated with: the ability of the Company to timely and successfully achieve or recognize the anticipated benefits of its ~~acquisition~~behalf of Tenet Medicines, Inc. and its technology transfer and exclusive license agreement with Beijing Mabworks Biotech Co., Ltd.; the Company’s ability to advance budoprutug and CLYM116 on the timelines expected or at all and to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other regulatory authorities; obtaining and maintaining the necessary approvals from investigational review boards at clinical trial sites and independent data safety monitoring boards; replicating in clinical trials positive results found in early-stage clinical trials or preclinical studies; competing successfully with other companies that are seeking to develop treatments for primary membranous nephropathy, immune thrombocytopenia, systemic lupus erythematosus, IgA nephropathy and other immune-mediated diseases; maintaining or protecting intellectual property rights related to budoprutug, CLYM116 and/or its other product candidates; managing expenses; changes in applicable laws or regulation; the possibility that the Company may be adversely affected by ~~other economic, business and/or competitive factors; and raising~~ the ~~substantial~~undersigned ~~additional~~hereunto ~~capital~~duly ~~needed, on the timeline necessary, to continue development of budoprutug, CLYM116 and any other product candidates the Company may develop~~authorized. For a discussion of other risks and uncertainties and other important factors, any of which could cause the Company’s actual results to differ materially from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in the Company’s most recent filings with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this Current Report on Form 8-K represent the Company’s views as of the date hereof and should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as required by law.

SIGNATURES


			Climb Bio, Inc.

Date:	November 6, 2025	By:	/s/ Aoife Brennan
			Aoife Brennan, M.B., Ch.B. President and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Filing Compare · Climb Bio, Inc.